CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hangzhou Jiuyuan Genetic Biopharm Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hangzhou Jiuyuan Genetic Biopharm Co Ltd
No. 23, No. 8 Avenue,
Baiyang Neighborhood, Qiantang District
Phone: +86 57186910099p:+86 57186910099 HANGZHOU, ZHJ  China Ticker: 25662566
Business Summary
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd, formerly Hangzhou Jiuyuan Gene Engineering Co Ltd, is a China-based company principally engaged in the research, development, manufacturing and commercialization of biopharmaceutical products and medical devices. The Company focuses on orthopedics, metabolic diseases, oncology and blood treatment. The Company's orthopedic products include Guyoudao bone repair materials. The Company's oncology products include Jilifen, Jijufen, Jiouting, Jifuwei, and Jitansu. The Company's blood products include Jipailin and Yinuojia. The Company's products are mainly used to treat diseases such as diabetes, multiple myeloma, thrombocytopenia, and neutropenia. The Company mainly operates its businesses in the domestic and overseas markets.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
3842 Orthopedic, prosthetic, and surgical appliances and supplies
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, General Manager HangFu 61 1/1/2024 2/1/2000
Deputy General Manager, General Manager - Pharmacy services, Executive Director WeiZhou 49 1/1/2024 1/1/2014
Deputy General Manager, Chief Manager - Manufacturing Center HuiLi 52 3/1/2022 10/1/2017
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,541 (As of 12/31/2024)
Outstanding Shares: 385,495,585 (As of 12/31/2024)
Stock Exchange: HKG
Fax Number: +86 57186911688


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 13, 2025